Skip to main content

Hepatitis C Viral RNA, Genotype

Test codes: 

  • 11348: Hepatitis C Virus RNA, Quantitative Real-Time PCR with Reflex to Genotype
  • 37811: Hepatitis C Virus RNA Genotype
  • 93871: Hepatitis C Virus RNA Genotype with Reflex to HCV NS5a Drug Resistance
  • 93873: Hepatitis C Viral RNA, Quantitative Real-Time PCR with Reflexes
  • 94345: Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype

Determination of hepatitis C genotype may be required to select the most appropriate direct-acting agent(s) (DAA) for the treatment of hepatitis C. For guidance, refer to the package inserts of the relevant DAAs or to the American Association for the study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) "Recommendations for Testing, Managing and Treating Hepatitis C ".1 A concurrent HCV viral load of 2,000 IU/mL is usually required for this test.

The HCV RNA genotype test can detect all 6 major HCV genotypes (1–6) and HCV subtypes 1a and 1b.

The HCV RNA genotype test is performed by nucleic acid extraction, reverse transcription, polymerase chain reaction (PCR) amplification, and Sanger DNA sequencing.

The HCV RNA genotype assay is designed to detect all 6 major HCV genotypes. The NS3, NS5a, and NS5b genotype assays, on the other hand, detect mutations associated with drug resistance.

Drug resistance genotype assays are not intended for determining HCV genotypes, as they are limited to specific HCV genotypes: genotype 1 for NS3 and NS5b, and genotypes 1 and 3 for NS5a.The Hepatitis C Viral RNA, Genotype assay (test code 37811) should be performed before ordering a drug resistance test.

For most HCV genotypes, a viral load of at least 2,000 IU/mL will enable successful detection of the HCV genotype. In some cases, the genotype will not be detected due to low viral load, mutations in the viral genome at PCR priming sites, or other undetermined factors.

The genotyping assay usually requires a minimum viral load of 2,000 IU/mL to successfully obtain a genotype. The limit of detection varies by genotype and ranges from 500 to 5,000 IU/mL.

Since the viral load assay used in this reflex test has a much lower limit of quantitation, it is possible for the patient to have a detectable viral load (below 2,000 IU/mL) and not have a reportable genotype result. Therefore, the Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype test (test code 94345) does not reflex to HCV genotype if the patient’s viral load is <2,000 IU/mL.

The reflex algorithm allows 3 important HCV tests to be completed, if necessary, with a single blood draw. Each of the 3 tests provides information that is important when a patient enters care.1

  • HCV antibody testing is the initial screening test. A positive result is consistent with prior resolved infection, active infection, or a false-positive antibody, but a supplemental test is needed to confirm active infection.
  • The reflex to quantitative HCV RNA testing serves 2 important functions: 1) as a supplemental test to confirm active infection in patients with a positive HCV antibody result and 2) to establish the baseline viral load (concentration of HCV virus in blood). Knowing the viral load at baseline helps physicians monitor response to therapy.
  • HCV genotype testing is used to inform treatment decisions.

The tests included in TC 94345 Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype are recommended for diagnosis and can be used to guide the selection of antiviral treatment.1 The reflex approach should improve the proportion of patients who have this complete series of important HCV tests performed.2

More guidance can be found in the AASLD and IDSA recommendations for testing, managing, and treating HCV.1

Reference

  1. AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Accessed September 29, 2025. http://www.hcvguidelines.org/
  2. Cartwright, EJ et al. Updated operational guidance for implementing CDC's recommendations on testing for hepatitis C virus infection. MMWR Morb Mortal Wkly Rep. 2023;72(28):766-768. doi:10.15585/mmwr.mm7228a2.

 

This FAQ is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on the physician’s education, clinical expertise, and assessment of the patient.

 

Document FAQS.21 Version: 4

Version 4 effective 12/09/2025 to present

Version 3 effective 05/19/2025 to 12/09/2025

Version 2 effective 12/26/2018 to 05/19/2025
Version 1 effective 10/2/2015 to 12/26/2018
Version 0 effective 01/24/2012 to 10/01/2015